<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03188744</url>
  </required_header>
  <id_info>
    <org_study_id>5557/2017</org_study_id>
    <nct_id>NCT03188744</nct_id>
  </id_info>
  <brief_title>Impact of Cancer Treatment on the Pelvic Floor Function in Survivors of Cervical Cancer</brief_title>
  <official_title>Impact of Cancer Treatment on the Pelvic Floor Function in Survivors of Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Pelvic floor muscle dysfunctions (PFMD) represent an important public health
      problem that manifests itself through lower urinary tract symptoms (LUTS), anorectal and
      sexual dysfunction. PFMD is a common problem in cervical cancer survivors (CC) with a
      negative impact on quality of life (QoL). Objective: This study aims to evaluate the effect
      of oncological treatment on the function of pelvic floor muscles (PFM) of survivors of CC.
      Methods: Patients diagnosed with CC, of any stage, histology and degree, accompanied by the
      Oncology Gynecology Service of the Hospital das Clínicas of the Medical School of Ribeirão
      Preto at the University of São Paulo, will be studied in the period between 2004 and 2014.
      Four study groups will be formed: (1) Patients with CC with PFMD; (2) Patients with CC
      without PFMD; : (3) Patients without CC with PFMD; (2) Patients without CC without PFMD.
      Non-cancer patients will be recruited into the community. For the analysis of the prevalence
      of PFMD will be applied to the discomfort Questionnaire on pelvic floor (IDPE-20) for
      evaluation of pelvic organ prolapse (POP) complaints, anorectal symptoms and urinary
      incontinence, and the Sexual Questionnaire for urinary incontinence and pelvic organ prolapse
      (PISQ -12) for evaluation of sexual function. Both questionnaires have already been validated
      for the Portuguese language and are specific for women with PFMD. The pelvic floor impact
      questionnaire (PFIQ-7) will also be applied to assess the impact of PFMD on quality of life,
      daily living activities and emotional health. For the evaluation of general QOL, the EORTC
      questionnaire QLQ-C30 and its specific module for patients with CC, QLQ-CX24 will be used.
      The evaluation of PFM function will include vaginal palpation (Modified Oxford Scale) and
      perineometry (Peritron).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pelvic floor muscles function</measure>
    <time_frame>Four months</time_frame>
    <description>Evaluated through vaginal palpation and perineometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life in the pelvic floor muscles dysfunction.</measure>
    <time_frame>Four months</time_frame>
    <description>Evaluated through application of the questionnaire PFIQ-7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of the pelvic floor muscles dysfunction.</measure>
    <time_frame>Four months</time_frame>
    <description>Evaluated through application of the questionnaires PSIQ-12 and PFID-20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall quality of life.</measure>
    <time_frame>Four months</time_frame>
    <description>Evaluated through application of the questionnaires EORTC QLQ-C30 and its specific module for patients with CC, QLQ-CX24 and the WHOQoL-BREF questionnaire.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Pelvic Floor Disorders</condition>
  <condition>Surgery</condition>
  <condition>Radiotherapy; Complications</condition>
  <condition>Chemotherapy Effect</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Patients with CC with PFMD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Patients with CC without PFMD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Patients without CC with PFMD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>Patients without CC without PFMD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assessment of the pelvic floor function</intervention_name>
    <description>Vaginal palpation and perineometry.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire application</intervention_name>
    <description>Questionnaires: EORTC, WHOQoL-BREF, PFID-20; PSIQ-12 and PFIQ-7.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women with CC with and without PFMD and women without CC with and without PFMD.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women diagnosed with CC; No distinction as to age, race, scholarity and religion;
             Women in follow-up at Clinical Hospital of Medical School of Ribeirão Preto of
             University São Paulo.

        Exclusion Criteria:

          -  Women who did not complete the proposed cancer treatment; Women who presented CC as
             the second malignant neoplasm; Pregnant women; Failure to respond to the proposed
             questionnaires.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harley Oliveira, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aline Ribeiro, MSc.</last_name>
    <phone>+5516981102877</phone>
    <email>alinemrib@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of São Paulo</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <zip>14040-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Aline Ribeiro, MSc</last_name>
      <phone>+55 35 998378748</phone>
      <email>alinemrib@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Aline Ribeiro, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Greimel ER, Kuljanic Vlasic K, Waldenstrom AC, Duric VM, Jensen PT, Singer S, Chie W, Nordin A, Bjelic Radisic V, Wydra D; European Organization for Research and Treatment of Cancer Quality-of-Life Group. The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24. Cancer. 2006 Oct 15;107(8):1812-22.</citation>
    <PMID>16977652</PMID>
  </reference>
  <results_reference>
    <citation>Arouca MA, Duarte TB, Lott DA, Magnani PS, Nogueira AA, Rosa-E-Silva JC, Brito LG. Validation and cultural translation for Brazilian Portuguese version of the Pelvic Floor Impact Questionnaire (PFIQ-7) and Pelvic Floor Distress Inventory (PFDI-20). Int Urogynecol J. 2016 Jul;27(7):1097-106. doi: 10.1007/s00192-015-2938-8. Epub 2016 Jan 19.</citation>
    <PMID>26782099</PMID>
  </results_reference>
  <results_reference>
    <citation>Santana GW, Aoki T, Auge AP. The Portuguese validation of the short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). Int Urogynecol J. 2012 Jan;23(1):117-21. doi: 10.1007/s00192-011-1505-1. Epub 2011 Jul 28.</citation>
    <PMID>21796471</PMID>
  </results_reference>
  <results_reference>
    <citation>Hazewinkel MH, Sprangers MA, Taminiau-Bloem EF, van der Velden J, Burger MP, Roovers JP. Reasons for not seeking medical help for severe pelvic floor symptoms: a qualitative study in survivors of gynaecological cancer. BJOG. 2010 Jan;117(1):39-46. doi: 10.1111/j.1471-0528.2009.02411.x.</citation>
    <PMID>19874292</PMID>
  </results_reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2017</study_first_posted>
  <last_update_submitted>December 18, 2018</last_update_submitted>
  <last_update_submitted_qc>December 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Aline Moreira Ribeiro</investigator_full_name>
    <investigator_title>MSc.</investigator_title>
  </responsible_party>
  <keyword>Cervical cancer</keyword>
  <keyword>Pelvic floor muscles</keyword>
  <keyword>Physiotherapy</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Pelvic Floor Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

